Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

Pirouz Daftarian, Marc Mansour, Anita C. Benoit, Bill Pohajdak, David W. Hoskin, Robert G. Brown, W. Martin Kast

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Human papillomavirus (HPV)-induced cervical cancer is the second most common cancer among women worldwide with half a million new cases per year. Despite the encouraging development of a preventive vaccine for HPV, a therapeutic vaccine for cervical cancer or pre-cancerous lesions remains a high priority. The preclinical study reported here used VacciMax® (VM) to deliver a peptide-based vaccine composed of an HPV 16 E7-derived cytotoxic T lymphocyte (CTL) epitope fused to the T helper epitope PADRE (FP) and combined with CpG or lipopeptide adjuvant. In the study, C57BL/6 mice received 0.5 million HPV 16-expressing C3 tumor cells. Mice were inoculated post-tumor challenge with a single s.c. injection of FP-CpG-VM on either day 4, 5, 6, 9, or 14. All mice that received the FP-CpG-VM vaccine were tumor-free to day 130 when the experiment was terminated. In contrast, only a minority of mice that received a control vaccine were tumor-free on day 60. Cytotoxicity assays, ELISPOT and intracellular staining for interferon (IFN)-γ showed the immune response was specific for the selected CTL epitope. All mice that received the FP-CpG-VM vaccine remained tumor-free when re-challenged with 6 million C3 cells. Cytotoxicity assays 4 months post-challenge showed that only splenocytes from mice inoculated with the FP-CpG-VM vaccine had high lysis activity. These results indicate that VacciMax® causes a rapid, robust, durable and therapeutic CTL response to HPV 16 E7 protein expressing tumors.

Original languageEnglish (US)
Pages (from-to)5235-5244
Number of pages10
JournalVaccine
Volume24
Issue number24
DOIs
StatePublished - Jun 12 2006
Externally publishedYes

Fingerprint

Human papillomavirus 16
cytotoxic T-lymphocytes
Cytotoxic T-Lymphocytes
Emulsions
Liposomes
emulsions
Oils
Vaccines
Cancer Vaccines
peptides
vaccines
Peptides
neoplasms
Water
T-Lymphocyte Epitopes
mice
Neoplasms
epitopes
Uterine Cervical Neoplasms
uterine cervical neoplasms

Keywords

  • Cervical cancer
  • Human papillomavirus
  • Immunotherapy
  • Liposome
  • Peptide
  • Theraputic
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. / Daftarian, Pirouz; Mansour, Marc; Benoit, Anita C.; Pohajdak, Bill; Hoskin, David W.; Brown, Robert G.; Kast, W. Martin.

In: Vaccine, Vol. 24, No. 24, 12.06.2006, p. 5235-5244.

Research output: Contribution to journalArticle

Daftarian, Pirouz ; Mansour, Marc ; Benoit, Anita C. ; Pohajdak, Bill ; Hoskin, David W. ; Brown, Robert G. ; Kast, W. Martin. / Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. In: Vaccine. 2006 ; Vol. 24, No. 24. pp. 5235-5244.
@article{ab00282927cd453aa23d6d4b07a70e0b,
title = "Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion",
abstract = "Human papillomavirus (HPV)-induced cervical cancer is the second most common cancer among women worldwide with half a million new cases per year. Despite the encouraging development of a preventive vaccine for HPV, a therapeutic vaccine for cervical cancer or pre-cancerous lesions remains a high priority. The preclinical study reported here used VacciMax{\circledR} (VM) to deliver a peptide-based vaccine composed of an HPV 16 E7-derived cytotoxic T lymphocyte (CTL) epitope fused to the T helper epitope PADRE (FP) and combined with CpG or lipopeptide adjuvant. In the study, C57BL/6 mice received 0.5 million HPV 16-expressing C3 tumor cells. Mice were inoculated post-tumor challenge with a single s.c. injection of FP-CpG-VM on either day 4, 5, 6, 9, or 14. All mice that received the FP-CpG-VM vaccine were tumor-free to day 130 when the experiment was terminated. In contrast, only a minority of mice that received a control vaccine were tumor-free on day 60. Cytotoxicity assays, ELISPOT and intracellular staining for interferon (IFN)-γ showed the immune response was specific for the selected CTL epitope. All mice that received the FP-CpG-VM vaccine remained tumor-free when re-challenged with 6 million C3 cells. Cytotoxicity assays 4 months post-challenge showed that only splenocytes from mice inoculated with the FP-CpG-VM vaccine had high lysis activity. These results indicate that VacciMax{\circledR} causes a rapid, robust, durable and therapeutic CTL response to HPV 16 E7 protein expressing tumors.",
keywords = "Cervical cancer, Human papillomavirus, Immunotherapy, Liposome, Peptide, Theraputic, Vaccine",
author = "Pirouz Daftarian and Marc Mansour and Benoit, {Anita C.} and Bill Pohajdak and Hoskin, {David W.} and Brown, {Robert G.} and Kast, {W. Martin}",
year = "2006",
month = "6",
day = "12",
doi = "10.1016/j.vaccine.2006.03.079",
language = "English (US)",
volume = "24",
pages = "5235--5244",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "24",

}

TY - JOUR

T1 - Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

AU - Daftarian, Pirouz

AU - Mansour, Marc

AU - Benoit, Anita C.

AU - Pohajdak, Bill

AU - Hoskin, David W.

AU - Brown, Robert G.

AU - Kast, W. Martin

PY - 2006/6/12

Y1 - 2006/6/12

N2 - Human papillomavirus (HPV)-induced cervical cancer is the second most common cancer among women worldwide with half a million new cases per year. Despite the encouraging development of a preventive vaccine for HPV, a therapeutic vaccine for cervical cancer or pre-cancerous lesions remains a high priority. The preclinical study reported here used VacciMax® (VM) to deliver a peptide-based vaccine composed of an HPV 16 E7-derived cytotoxic T lymphocyte (CTL) epitope fused to the T helper epitope PADRE (FP) and combined with CpG or lipopeptide adjuvant. In the study, C57BL/6 mice received 0.5 million HPV 16-expressing C3 tumor cells. Mice were inoculated post-tumor challenge with a single s.c. injection of FP-CpG-VM on either day 4, 5, 6, 9, or 14. All mice that received the FP-CpG-VM vaccine were tumor-free to day 130 when the experiment was terminated. In contrast, only a minority of mice that received a control vaccine were tumor-free on day 60. Cytotoxicity assays, ELISPOT and intracellular staining for interferon (IFN)-γ showed the immune response was specific for the selected CTL epitope. All mice that received the FP-CpG-VM vaccine remained tumor-free when re-challenged with 6 million C3 cells. Cytotoxicity assays 4 months post-challenge showed that only splenocytes from mice inoculated with the FP-CpG-VM vaccine had high lysis activity. These results indicate that VacciMax® causes a rapid, robust, durable and therapeutic CTL response to HPV 16 E7 protein expressing tumors.

AB - Human papillomavirus (HPV)-induced cervical cancer is the second most common cancer among women worldwide with half a million new cases per year. Despite the encouraging development of a preventive vaccine for HPV, a therapeutic vaccine for cervical cancer or pre-cancerous lesions remains a high priority. The preclinical study reported here used VacciMax® (VM) to deliver a peptide-based vaccine composed of an HPV 16 E7-derived cytotoxic T lymphocyte (CTL) epitope fused to the T helper epitope PADRE (FP) and combined with CpG or lipopeptide adjuvant. In the study, C57BL/6 mice received 0.5 million HPV 16-expressing C3 tumor cells. Mice were inoculated post-tumor challenge with a single s.c. injection of FP-CpG-VM on either day 4, 5, 6, 9, or 14. All mice that received the FP-CpG-VM vaccine were tumor-free to day 130 when the experiment was terminated. In contrast, only a minority of mice that received a control vaccine were tumor-free on day 60. Cytotoxicity assays, ELISPOT and intracellular staining for interferon (IFN)-γ showed the immune response was specific for the selected CTL epitope. All mice that received the FP-CpG-VM vaccine remained tumor-free when re-challenged with 6 million C3 cells. Cytotoxicity assays 4 months post-challenge showed that only splenocytes from mice inoculated with the FP-CpG-VM vaccine had high lysis activity. These results indicate that VacciMax® causes a rapid, robust, durable and therapeutic CTL response to HPV 16 E7 protein expressing tumors.

KW - Cervical cancer

KW - Human papillomavirus

KW - Immunotherapy

KW - Liposome

KW - Peptide

KW - Theraputic

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33744505292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744505292&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.03.079

DO - 10.1016/j.vaccine.2006.03.079

M3 - Article

VL - 24

SP - 5235

EP - 5244

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 24

ER -